Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin for prevention of anthracycline-induced cardiac dysfunction in breast cancer
IRCT20191002044961N2Phase 4Recruiting
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in breast cancer comparing Rosuvastatin with Placebo (2 arms). Primary endpoint: Incidence of cancer therapy-related cardiac dysfunction. Started Nov 2025; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on IRCT20191002044961N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191002044961N2.